Clinical Utility and Analytical Challenges in Measurement of Cerebrospinal Fluid Amyloid-β(1–42) and τ Proteins as Alzheimer Disease Biomarkers

Eitemau Tebyg

• Qualification of a Surrogate Matrix-Based Absolute Quantification Method for Amyloid-β(42) in Human Cerebrospinal Fluid Using 2D UPLC-Tandem Mass Spectrometry
  gan: Korecka, Magdalena, et al.
  Cyhoeddwyd: (2014)
• Comparison of Cerebrospinal Fluid Levels of Tau and Aß(1-42) in Alzheimer’s disease and Frontotemporal Degeneration Using Two Analytical Platforms
  gan: Irwin, David J., et al.
  Cyhoeddwyd: (2012)
• Comparison of analytical platforms for cerebrospinal fluid measures of Aβ(1-42), total tau and p-tau(181) for identifying Alzheimer’s disease amyloid plaque pathology
  gan: Fagan, Anne M., et al.
  Cyhoeddwyd: (2011)
• Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker
  gan: Toledo, Jon B, et al.
  Cyhoeddwyd: (2013)
• Nonlinear Association Between Cerebrospinal Fluid and Florbetapir F-18 β-Amyloid Measures Across the Spectrum of Alzheimer Disease
  gan: Toledo, Jon B., et al.
  Cyhoeddwyd: (2015)